182 related articles for article (PubMed ID: 22634438)
1. Meningococcal polysaccharide vaccine failure in a patient with C7 deficiency and a decreased anti-capsular antibody response.
Keiser PB; Broderick M
Hum Vaccin Immunother; 2012 May; 8(5):582-6. PubMed ID: 22634438
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
[TBL] [Abstract][Full Text] [Related]
3. Meningococcal serogroup A, C, W, and Y serum bactericidal antibody profiles in Hajj pilgrims.
Memish ZA; Yezli S; Almasri M; Assiri A; Turkestani A; Findlow H; Bai X; Borrow R
Int J Infect Dis; 2014 Nov; 28():171-5. PubMed ID: 25307887
[TBL] [Abstract][Full Text] [Related]
4. [Meningococcemia and meningitis due to Neisseria meningitidis W135 developed in two cases vaccinated with bivalent (A/C) meningococcal vaccine].
Turhan V; Acar A; Kılıç A; Budak S; Oncül O; Haznedaroğlu T; Görenek L
Mikrobiyol Bul; 2010 Jul; 44(3):473-8. PubMed ID: 21063998
[TBL] [Abstract][Full Text] [Related]
5. Immune responses following meningococcal serogroups A, C, Y and W polysaccharide vaccination in C2-deficient persons: evidence for increased levels of serum bactericidal antibodies.
Brodszki N; Skattum L; Bai X; Findlow H; Borrow R; Jönsson G
Vaccine; 2015 Apr; 33(15):1839-45. PubMed ID: 25707694
[TBL] [Abstract][Full Text] [Related]
6. Serum bactericidal antibody response to serogroup C polysaccharide meningococcal vaccination in children with primary antibody deficiencies.
Rezaei N; Aghamohammadi A; Siadat SD; Nejati M; Ahmadi H; Moin M; Pourpak Z; Kamali S; Norouzian D; Tabaraei B; Read RC
Vaccine; 2007 Jul; 25(29):5308-14. PubMed ID: 17574314
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097
[TBL] [Abstract][Full Text] [Related]
8. The role of complement in anti-bacterial defence.
D'Amelio R; Biselli R
Ann Ital Med Int; 1994; 9(3):173-7. PubMed ID: 7946895
[TBL] [Abstract][Full Text] [Related]
9. Vaccination and the role of capsular polysaccharide antibody in prevention of recurrent meningococcal disease in late complement component-deficient individuals.
Andreoni J; Käyhty H; Densen P
J Infect Dis; 1993 Jul; 168(1):227-31. PubMed ID: 8515116
[TBL] [Abstract][Full Text] [Related]
10. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
Cohen R; Levy C
Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368
[TBL] [Abstract][Full Text] [Related]
11. Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005.
Ceyhan M; Yildirim I; Balmer P; Riley C; Laher G; Andrews N; Borrow R; Kurt N; Turgut M; Aydogan A; Ecevit C; Uysal G; Schultze V
Vaccine; 2007 Oct; 25(41):7233-7. PubMed ID: 17707957
[TBL] [Abstract][Full Text] [Related]
12. Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine.
Fijen CA; Kuijper EJ; Drogari-Apiranthitou M; Van Leeuwen Y; Daha MR; Dankert J
Clin Exp Immunol; 1998 Dec; 114(3):362-9. PubMed ID: 9844044
[TBL] [Abstract][Full Text] [Related]
13. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
[TBL] [Abstract][Full Text] [Related]
14. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents.
Jacobson RM; Jackson LA; Reisinger K; Izu A; Odrljin T; Dull PM
Pediatr Infect Dis J; 2013 Apr; 32(4):e170-7. PubMed ID: 23114372
[TBL] [Abstract][Full Text] [Related]
15. MenACWY-TT vaccine for active immunization against invasive meningococcal disease.
Papaevangelou V; Spyridis N
Expert Rev Vaccines; 2012 May; 11(5):523-37. PubMed ID: 22827239
[TBL] [Abstract][Full Text] [Related]
16. Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT).
Østergaard L; Van der Wielen M; Bianco V; Miller JM
Int J Infect Dis; 2013 Mar; 17(3):e173-6. PubMed ID: 23246368
[TBL] [Abstract][Full Text] [Related]
17. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.
Baxter R; Reisinger K; Block SL; Izu A; Odrljin T; Dull P
J Pediatr; 2014 Jun; 164(6):1409-15.e4. PubMed ID: 24657122
[TBL] [Abstract][Full Text] [Related]
18. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.
Tunheim G; Arnemo M; Næss LM; Fjeldheim ÅK; Nome L; Bolstad K; Aase A; Mandiarote A; González H; González D; García L; Cardoso D; Norheim G; Rosenqvist E
Vaccine; 2013 Dec; 31(51):6097-106. PubMed ID: 24120679
[TBL] [Abstract][Full Text] [Related]
19. Novel quadrivalent meningococcal A, C, W-135 and Y glycoconjugate vaccine for the broader protection of adolescents and adults.
Pace D
Future Microbiol; 2010 Nov; 5(11):1629-40. PubMed ID: 21133685
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of the immunogenicity and safety of a new trivalent meningococcal polysaccharide vaccine.
Chandramohan D; Hodgson A; Coleman P; Baiden R; Asante K; Awine E; Owusu-Agyei S; Boutriau D; Nelson CB; Greenwood B
Vaccine; 2007 Sep; 25 Suppl 1():A83-91. PubMed ID: 17521782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
